Dynamic Advisor Solutions LLC Cuts Stake in Sanofi $SNY

Dynamic Advisor Solutions LLC cut its stake in Sanofi (NASDAQ:SNY) by 87.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 7,290 shares of the company’s stock after selling 52,401 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Sanofi were worth $353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of SNY. Raymond James Financial Inc. increased its holdings in shares of Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares during the last quarter. Mondrian Investment Partners LTD purchased a new position in shares of Sanofi in the 3rd quarter worth $171,742,000. Natixis Advisors LLC boosted its holdings in Sanofi by 11.8% in the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock valued at $146,952,000 after acquiring an additional 327,569 shares during the last quarter. Equity Investment Corp grew its position in Sanofi by 3.0% during the third quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock valued at $122,139,000 after acquiring an additional 75,255 shares during the period. Finally, Brandes Investment Partners LP grew its position in Sanofi by 9.1% during the second quarter. Brandes Investment Partners LP now owns 2,483,767 shares of the company’s stock valued at $119,992,000 after acquiring an additional 208,090 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $46.78 on Friday. The company has a market cap of $114.10 billion, a P/E ratio of 12.99, a PEG ratio of 1.16 and a beta of 0.45. The business’s 50-day simple moving average is $46.31 and its 200 day simple moving average is $47.99. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. Sanofi has a one year low of $43.32 and a one year high of $55.99.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research reports. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a report on Friday, January 16th. UBS Group restated a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Citigroup began coverage on shares of Sanofi in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and an average price target of $61.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.